Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10729742
APP PUB NO 20170014474A1
SERIAL NO

15285561

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ACTITREXX GMBHLANGENBECKSTRASSE 1 MAINZ 55131

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Becker, Christian Mainz, DE 45 150
Bopp, Tobias Aabergen, DE 4 5
Jonuleit, Helmut Russelsheim, DE 12 180
Schmitt, Edgar Mainz, DE 32 376
Schneider, Franz-Josef Laupheim, DE 6 16

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 4, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 4, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00